Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments

ÖZEN S., KONE-PAUT I., Gül A.

SEMINARS IN ARTHRITIS AND RHEUMATISM, cilt.47, sa.1, ss.115-120, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 47 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.semarthrit.2017.03.006
  • Dergi Adı: SEMINARS IN ARTHRITIS AND RHEUMATISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.115-120
  • Anahtar Kelimeler: Colchicine resistance, Familial Mediterranean fever, Interleukin-1, Second-line therapy, INTRAVENOUS COLCHICINE, ORAL COLCHICINE, CHILDREN, CANAKINUMAB, DRUG, EFFICACY, THERAPY, TRIAL, FMF, ADOLESCENTS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory syndrome characterized by recurrent serositis or arthritis attacks and, in some patients, chronic subclinical inflammation that predisposes to secondary amyloidosis. Colchicine is the gold standard of treatment, which reduces attack frequency and amyloidosis risk. However, up to 5% of patients are considered resistant or inadequately respond to colchicine, and some others cannot tolerate the side effects of effective doses of colchicine (colchicine intolerant).